A real-world study to assess effectiveness and safety in non-valvular atrial fibrillation patients in Thailand receiving non-vitamin K antagonist oral anticoagulants and warfarin
Latest Information Update: 02 Nov 2020
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary) ; Warfarin
- Indications Embolism; Stroke; Thromboembolism
- Focus Adverse reactions; Therapeutic Use
- Acronyms REAL-T AF
- 02 Nov 2020 New trial record
- 28 Oct 2020 Primary endpoint (Effectiveness outcome: First occurrence of stroke or systemic embolism (SSE)) has not been met, according to results published in the Clinical Pharmacology and Therapeutics
- 28 Oct 2020 Results published in the Clinical Pharmacology and Therapeutics